title: Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer.
authors.affiliation: Gustave Roussy Cancer Campus, Villejuif, France Laboratory of Immune monitoring in Oncology UMS 3655 CNRS/US 23 INSERM Gustave Roussy Cancer Campus, Villejuif, France Cell Therapy Unit, Gustave Roussy Cancer Campus, Villejuif, France nathalie.chaput@gustaveroussy.fr.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Chaput
authors.affiliation: Gustave Roussy Cancer Campus, Villejuif, France Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.
authors.forename: Aurelien
authors.initials: A
authors.lastname: Marabelle
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung; D006801:Humans; D008175:Lung Neoplasms; D011379:Prognosis; D012420:Running